{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T11:32:20Z","timestamp":1791804740036,"version":"4.3.4"},"reference-count":40,"publisher":"BMJ","issue":"9","funder":[{"DOI":"10.13039\/100019368","name":"Applebaum Foundation","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/100019368","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000065","name":"National Institute of Neurological Disorders and Stroke","doi-asserted-by":"publisher","award":["R01NS113828"],"award-info":[{"award-number":["R01NS113828"]}],"id":[{"id":"10.13039\/100000065","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Neurol Neurosurg Psychiatry"],"accepted":{"date-parts":[[2026,3,30]]},"published-print":{"date-parts":[[2026,9]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Psychiatric comorbidities are increasingly recognised in demyelinating diseases, yet their frequency and timing in myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) are not well defined. We aimed to characterise the spectrum and temporal pattern of psychiatric illness in MOGAD and compare to multiple sclerosis (MS) and neuromyelitis optica spectrum disorder (NMOSD) with aquaporin-4 antibody (AQP4-IgG).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a cross-sectional study of patients with MOGAD (n=388), age-matched and sex-matched MS (n=257) and AQP4-IgG-positive NMOSD (n=58) evaluated at Mayo Clinic (1991\u20132025). Psychiatric diagnoses, timing relative to the first attack and patient-reported outcomes were extracted from electronic health records (EHRs). Complementary analyses were conducted using the NeuroBlu real-world EHR database.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Among 388 patients with MOGAD, 54.8% had \u22651 psychiatric disorder, most commonly anxiety (47.7%), depression (36.6%) and attention-deficit\/hyperactivity disorder (ADHD, 9%). After the first attack, 33.3% of patients with MOGAD developed a new psychiatric disorder, often within the first year. MOGAD showed a lower frequency of depression versus MS (36.6% vs 47.5%, p=0.02) but similar rates of anxiety and ADHD. Temporal patterns differed: psychiatric disorders often appeared years before onset in MS but clustered shortly after onset in MOGAD. NeuroBlu analyses supported high rates of psychiatric disorders across the three conditions.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Psychiatric comorbidities are common in MOGAD, particularly depression and anxiety, typically emerging close after onset, whereas in MS they often preceded onset by years. These findings underscore the need for routine psychiatric screening in MOGAD and highlight unresolved questions regarding whether, and to what extent, MOG-IgG-mediated inflammatory demyelination contributes to psychiatric vulnerability.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/jnnp-2025-338335","type":"journal-article","created":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T17:20:42Z","timestamp":1775755242000},"page":"817-826","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":2,"title":["Psychiatric comorbidities cluster early after onset in MOGAD: a cross-sectional comparative study with MS and NMOSD"],"prefix":"10.1136","volume":"97","author":[{"given":"Moritz","family":"Niederschweiberer","sequence":"first","affiliation":[{"name":"Neurology, Center for Multiple Sclerosis and Autoimmune Neurology, Mayo Clinic, Rochester, Minnesota, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cicek","family":"Bakir","sequence":"additional","affiliation":[{"name":"Psychiatry and Psychology, Mayo Clinic, Rochester, Minnesota, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nisa","family":"Vorasoot","sequence":"additional","affiliation":[{"name":"Neurology, Laboratory Medicine and Pathology and Center for Multiple Sclerosis and Autoimmune Neurology, Mayo Clinic, Rochester, Minnesota, USA"},{"name":"Department of Medicine, Khon Kaen University, Nai Mueang, Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9342-2410","authenticated-orcid":false,"given":"Laura","family":"Cacciaguerra","sequence":"additional","affiliation":[{"name":"Neurology, Laboratory Medicine and Pathology and Center for Multiple Sclerosis and Autoimmune Neurology, Mayo Clinic, Rochester, Minnesota, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan-Mendelt","family":"Tillema","sequence":"additional","affiliation":[{"name":"Neurology, Center for Multiple Sclerosis and Autoimmune Neurology, Mayo Clinic, Rochester, Minnesota, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreu","family":"Vilaseca","sequence":"additional","affiliation":[{"name":"Neurology, Laboratory Medicine and Pathology and Center for Multiple Sclerosis and Autoimmune Neurology, Mayo Clinic, Rochester, Minnesota, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0607-904X","authenticated-orcid":false,"given":"Smathorn","family":"Thakolwiboon","sequence":"additional","affiliation":[{"name":"Neurology, Center for Multiple Sclerosis and Autoimmune Neurology, Mayo Clinic, Rochester, Minnesota, USA"},{"name":"Neurology, Mayo Clinic Health System, La Crosse, Wisconsin, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5053-8544","authenticated-orcid":false,"given":"Albert","family":"Aboseif","sequence":"additional","affiliation":[{"name":"Neurology, Center for Multiple Sclerosis and Autoimmune Neurology, Mayo Clinic, Rochester, Minnesota, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9549-6648","authenticated-orcid":false,"given":"Stephanie B","family":"Syc-Mazurek","sequence":"additional","affiliation":[{"name":"Neurology, Ophthalmology and Center for Multiple Sclerosis and Autoimmune Neurology, Mayo Clinic, Rochester, Minnesota, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William A","family":"Rees","sequence":"additional","affiliation":[{"name":"Center for Multiple Sclerosis and Autoimmune Neurology, Mayo Clinic, Rochester, Minnesota, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael R","family":"Basso","sequence":"additional","affiliation":[{"name":"Psychiatry and Psychology, Mayo Clinic, Rochester, Minnesota, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A Sebastian","family":"Lopez-Chiriboga","sequence":"additional","affiliation":[{"name":"Center for Multiple Sclerosis and Autoimmune Neurology, Mayo Clinic, Rochester, Minnesota, USA"},{"name":"Neurology, Mayo Clinic, Jacksonville, Florida, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dean M","family":"Wingerchuk","sequence":"additional","affiliation":[{"name":"Neurology, Mayo Clinic, Scottsdale, Arizona, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8141-2394","authenticated-orcid":false,"given":"W Oliver","family":"Tobin","sequence":"additional","affiliation":[{"name":"Neurology, Center for Multiple Sclerosis and Autoimmune Neurology, Mayo Clinic, Rochester, Minnesota, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul E","family":"Croarkin","sequence":"additional","affiliation":[{"name":"Psychiatry and Psychology, Mayo Clinic, Rochester, Minnesota, USA"},{"name":"Mayo Clinic Minnesota Children\u2019s Center, Rochester, Minnesota, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Sagen","sequence":"additional","affiliation":[{"name":"Center for Multiple Sclerosis and Autoimmune Neurology, Mayo Clinic, Rochester, Minnesota, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6140-5584","authenticated-orcid":false,"given":"Sean J","family":"Pittock","sequence":"additional","affiliation":[{"name":"Neurology, Laboratory Medicine and Pathology and Center for Multiple Sclerosis and Autoimmune Neurology, Mayo Clinic, Rochester, Minnesota, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John J","family":"Chen","sequence":"additional","affiliation":[{"name":"Neurology, Ophthalmology and Center for Multiple Sclerosis and Autoimmune Neurology, Mayo Clinic, Rochester, Minnesota, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6661-2910","authenticated-orcid":false,"given":"Eoin P","family":"Flanagan","sequence":"additional","affiliation":[{"name":"Neurology, Laboratory Medicine and Pathology and Center for Multiple Sclerosis and Autoimmune Neurology, Mayo Clinic, Rochester, Minnesota, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2026,4,9]]},"reference":[{"key":"2026081302150841000_97.9.817.1","doi-asserted-by":"publisher","DOI":"10.1016\/s1474-4422(22)00431-8"},{"key":"2026081302150841000_97.9.817.2","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1007\/s00415-024-12861-9","article-title":"MOG antibody-associated disease epidemiology in Olmsted County, USA, and Martinique","volume":"272","author":"Cacciaguerra","year":"2025","journal-title":"J Neurol"},{"key":"2026081302150841000_97.9.817.3","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2022.885218"},{"key":"2026081302150841000_97.9.817.4","doi-asserted-by":"publisher","DOI":"10.1007\/s11121-011-0231-8"},{"key":"2026081302150841000_97.9.817.5","doi-asserted-by":"publisher","DOI":"10.1186\/s12991-021-00374-y"},{"key":"2026081302150841000_97.9.817.6","doi-asserted-by":"crossref","first-page":"102128","DOI":"10.1016\/j.msard.2020.102128","article-title":"Evaluation of types of psychological disorders in patients with neuromyelitis optica spectrum disorder (NMOSD)","volume":"42","author":"Ebadi","year":"2020","journal-title":"Mult Scler Relat Disord"},{"key":"2026081302150841000_97.9.817.7","doi-asserted-by":"crossref","first-page":"1120541","DOI":"10.3389\/fnins.2023.1120541","article-title":"The prevalence and risk factors of anxiety in multiple sclerosis: A systematic review and meta-analysis","volume":"17","author":"Zhang","year":"2023","journal-title":"Front Neurosci"},{"key":"2026081302150841000_97.9.817.8","doi-asserted-by":"crossref","first-page":"102904","DOI":"10.1016\/j.msard.2021.102904","article-title":"Depression in multiple sclerosis: Is one approach for its management enough?","volume":"51","author":"Jones","year":"2021","journal-title":"Mult Scler Relat Disord"},{"key":"2026081302150841000_97.9.817.9","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1001\/jamaneurol.2024.2920","article-title":"Comorbidity and Disease Activity in Multiple Sclerosis","volume":"81","author":"Salter","year":"2024","journal-title":"JAMA Neurol"},{"key":"2026081302150841000_97.9.817.10","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1007\/s00415-025-13233-7","article-title":"Management and burden of disease in people with myelin oligodendrocyte glycoprotein antibody-associated disease: data from an international, cross-sectional survey","volume":"272","author":"Paul","year":"2025","journal-title":"J Neurol"},{"key":"2026081302150841000_97.9.817.11","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(25)00270-4"},{"key":"2026081302150841000_97.9.817.12","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000001729"},{"key":"2026081302150841000_97.9.817.13","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.jad.2020.01.101","article-title":"Minimally important differences and severity thresholds are estimated for the PROMIS depression scales from three randomized clinical trials","volume":"266","author":"Kroenke","year":"2020","journal-title":"J Affect Disord"},{"key":"2026081302150841000_97.9.817.14","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2021-057227","article-title":"NeuroBlu, an electronic health record (EHR) trusted research environment (TRE) to support mental healthcare analytics with real-world data","volume":"12","author":"Patel","year":"2022","journal-title":"BMJ Open"},{"key":"2026081302150841000_97.9.817.15","doi-asserted-by":"publisher","DOI":"10.1111\/ene.14729"},{"key":"2026081302150841000_97.9.817.16","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2024.105775"},{"key":"2026081302150841000_97.9.817.17","first-page":"20552173241274605","article-title":"Quality of life is impaired in myelin oligodendrocyte glycoprotein antibody associated disease","volume":"10","author":"Said","year":"2024","journal-title":"Mult Scler J Exp Transl Clin"},{"key":"2026081302150841000_97.9.817.18","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm7224a1"},{"key":"2026081302150841000_97.9.817.19","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.62.6.593"},{"key":"2026081302150841000_97.9.817.20","doi-asserted-by":"crossref","first-page":"1383078","DOI":"10.3389\/fpubh.2024.1383078","article-title":"Depression in persons with disabilities: a scoping review","volume":"12","author":"Asdaq","year":"2024","journal-title":"Front Public Health"},{"key":"2026081302150841000_97.9.817.21","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1007\/s40120-025-00770-6","article-title":"Patient Experience of Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease: Qualitative Patient and Clinician Interviews Informing the Development of a Conceptual Model","volume":"14","author":"Bennett","year":"2025","journal-title":"Neurol Ther"},{"key":"2026081302150841000_97.9.817.22","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1007\/s00415-024-12803-5","article-title":"Visual quality of life in NMOSD and MOGAD: profiles, dynamics and associations with ageing and vision","volume":"272","author":"Nicolescu","year":"2024","journal-title":"J Neurol"},{"key":"2026081302150841000_97.9.817.23","doi-asserted-by":"crossref","DOI":"10.1136\/bmjno-2025-001193","article-title":"Dyadic Coping of NMOSD and MOGAD patients and their partners: a sociological and psychological examination of strategies (CoMMOnsense-Study)","volume":"7","author":"Walz","year":"2025","journal-title":"BMJ Neurol Open"},{"key":"2026081302150841000_97.9.817.24","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1007\/s40120-023-00474-9","article-title":"Patient Pathway to Diagnosis of Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD): Findings from a Multinational Survey of 204 Patients","volume":"12","author":"Santoro","year":"2023","journal-title":"Neurol Ther"},{"key":"2026081302150841000_97.9.817.25","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1007\/s00415-023-12173-4","article-title":"Prodromal multiple sclerosis: considerations and future utility","volume":"271","author":"Harding","year":"2024","journal-title":"J Neurol"},{"key":"2026081302150841000_97.9.817.26","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1177\/1352458520908163","article-title":"Fatigue, sleep disorders, anaemia and pain in the multiple sclerosis prodrome","volume":"27","author":"Yusuf","year":"2021","journal-title":"Mult Scler"},{"key":"2026081302150841000_97.9.817.27","first-page":"e2026","article-title":"Psychiatric Comorbidity During the Prodromal Period in Patients With Multiple Sclerosis","volume":"101","author":"Chertcoff","year":"2023","journal-title":"Neurology (ECronicon)"},{"key":"2026081302150841000_97.9.817.28","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpsychires.2015.05.008"},{"key":"2026081302150841000_97.9.817.29","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1001\/jamaneurol.2019.3238","article-title":"Serum Neurofilament Light Chain Levels in Patients With Presymptomatic Multiple Sclerosis","volume":"77","author":"Bjornevik","year":"2020","journal-title":"JAMA Neurol"},{"key":"2026081302150841000_97.9.817.30","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1038\/s41591-025-04014-w","article-title":"Myelin injury precedes axonal injury and symptomatic onset in multiple sclerosis","volume":"32","author":"Abdelhak","year":"2026","journal-title":"Nat Med"},{"key":"2026081302150841000_97.9.817.31","doi-asserted-by":"publisher","DOI":"10.1080\/15374416.2024.2335625"},{"key":"2026081302150841000_97.9.817.32","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/S2215-0366(17)30049-4","article-title":"Subcortical brain volume differences in participants with attention deficit hyperactivity disorder in children and adults: a cross-sectional mega-analysis","volume":"4","author":"Hoogman","year":"2017","journal-title":"Lancet Psychiatry"},{"key":"2026081302150841000_97.9.817.33","doi-asserted-by":"publisher","DOI":"10.1038\/s41380-023-02138-4"},{"key":"2026081302150841000_97.9.817.34","doi-asserted-by":"publisher","DOI":"10.1080\/09540261.2022.2040450"},{"key":"2026081302150841000_97.9.817.35","doi-asserted-by":"crossref","first-page":"100847","DOI":"10.1016\/j.ssmph.2021.100847","article-title":"Barriers to healthcare access among U.S. adults with mental health challenges: A population-based study","volume":"15","author":"Coombs","year":"2021","journal-title":"SSM Popul Health"},{"key":"2026081302150841000_97.9.817.36","doi-asserted-by":"crossref","first-page":"103994","DOI":"10.1016\/j.msard.2022.103994","article-title":"The impact of socioeconomic status on subsequent neurological outcomes in multiple sclerosis","volume":"65","author":"Boorgu","year":"2022","journal-title":"Mult Scler Relat Disord"},{"key":"2026081302150841000_97.9.817.37","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2020.00778"},{"key":"2026081302150841000_97.9.817.38","doi-asserted-by":"publisher","DOI":"10.1007\/s00401-020-02132-y"},{"key":"2026081302150841000_97.9.817.39","doi-asserted-by":"crossref","first-page":"2166","DOI":"10.1002\/acn3.52137","article-title":"Cortical atrophy patterns in myelin oligodendrocyte glycoprotein antibody-associated disease","volume":"11","author":"Schneider","year":"2024","journal-title":"Ann Clin Transl Neurol"},{"key":"2026081302150841000_97.9.817.40","doi-asserted-by":"crossref","first-page":"14","DOI":"10.3390\/jcm14072445","article-title":"Brain Volume Measures in Adults with MOG-Antibody-Associated Disease: A Longitudinal Multicenter Study","volume":"14","author":"Orlandi","year":"2025","journal-title":"J Clin Med"}],"container-title":["Journal of Neurology, Neurosurgery &amp; Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jnnp-2025-338335","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T09:16:11Z","timestamp":1786612571000},"score":1,"resource":{"primary":{"URL":"https:\/\/jnnp.bmj.com\/lookup\/doi\/10.1136\/jnnp-2025-338335"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,9]]},"references-count":40,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2026,8,13]]},"published-print":{"date-parts":[[2026,9]]}},"alternative-id":["10.1136\/jnnp-2025-338335"],"URL":"https:\/\/doi.org\/10.1136\/jnnp-2025-338335","relation":{},"ISSN":["0022-3050","1468-330X"],"issn-type":[{"value":"0022-3050","type":"print"},{"value":"1468-330X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,9]]}}}